Fig. 1.
Metformin use was associated with a lesser cognitive decline in patients with prodromal Alzheimer’s disease. A Biplot obtained from a principal component analysis performed on 810 MCIAD subjects. Black dots represent patients receiving metformin. B Box plots indicating the mean value of principal component 1 and principal component 2 for MCIAD-metformin patients (n = 55). *p < 0.05; ns, non-significant differences (one-sample t-test compared with a theoretical mean of zero). C Standardized coefficient obtained for each variable included in the principal component analysis. Note that the values from the Trail Making Test A used for this analysis were inverted